Company: PSTV
Filing Date: 2025-06-20
Form Type: S-1/A
Source: 0001193125-25-142935
Chunk: 6

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-06-20
Form: S-1/A
Chunk 6
---
, Houston, Texas 77051, and our telephone number is (737) 255-7194. We maintain a website at www.plustherapeutics.com. We make available free
of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K, and amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as
reasonably practicable after we electronically file such material with, or furnish such material to, the SEC. These reports and other information are also available, free of charge, at www.sec.gov. Information contained on, or that can be accessed
through, the websites referenced in this prospectus are not a part of, or incorporated by reference into, this prospectus.

1

THE OFFERING

| Shares of our common stock offered by the selling stockholder | Up to 17,000,000 shares of our common stock, subject to certain limitations described in this prospectus, which we may issue and sell to Lincoln Park from time to time, at our sole discretion, during the 36-month period that began on the 
 Commencement Date in accordance with the Purchase Agreement.                                                                                                                                                                                  |

| Shares of our common stock outstanding prior to this offering (as of June 17, 2025) | 50,998,468 shares of our common stock. |

| Shares of our common stock to be outstanding after this offering | 67,998,468 shares of our common stock, assuming the sale of all the shares of common stock registered hereunder to Lincoln Park under the Purchase Agreement. The actual number of shares outstanding after this offering will vary depending upon 
 the actual number of shares we sell to Lincoln Park under the Purchase Agreement after the date of this prospectus.                                                                                                                                |

| Use of proceeds | We will receive no proceeds from the sale of shares of our common stock by Lincoln Park in this offering. We may receive, initially, aggregate gross proceeds of up to the Initial Available Amount and, upon receipt of the full amount thereof,        
 additional aggregate gross proceeds of up to the Additional Available Amount (for total aggregate gross proceeds of up to the Total Available Amount) from sales of shares of our common stock we make to Lincoln Park, if any, pursuant to the Purchase 
 Agreement, assuming that we sell the full amount of our common stock that we have the right